Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.36% | 28.52% | 40.57% | -33.73% | 8.53% |
| Total Depreciation and Amortization | -1.99% | 48.58% | -3.11% | -32.32% | -12.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 283.58% | -201.18% | -185.82% | -49.26% | -138.74% |
| Change in Net Operating Assets | 396.84% | -249.37% | -189.39% | -152.85% | -62.30% |
| Cash from Operations | -33.64% | -103.57% | -129.65% | -115.41% | -84.34% |
| Capital Expenditure | -- | 100.00% | 100.00% | 145.73% | -39.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 135.17% | 135.17% | 159.78% | 9.62% |
| Total Debt Issued | -- | -100.00% | 3,050.31% | 443.16% | -- |
| Total Debt Repaid | 54.21% | -118.40% | -118.40% | -118.40% | -118.40% |
| Issuance of Common Stock | -53.82% | 340.65% | 158.32% | 72.14% | 129.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | -65.46% | 244.89% | 181.45% | 204.90% | 207.96% |
| Foreign Exchange rate Adjustments | -424.59% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -200.00% | 200.00% | -- | -- |
| Net Change in Cash | -181.35% | 2,291.51% | 4,039.86% | 4,617.87% | 1,361.81% |